Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); antibody identification by qualitative panel using complete HLA phenotypes, HLA Class II
CPT4 code
Name of the Procedure:
Antibody to human leukocyte antigens (HLA), solid phase assays; antibody identification by qualitative panel using complete HLA phenotypes, HLA Class II. Commonly referred to as HLA antibody testing or HLA antibody identification.
Summary
This procedure involves identifying antibodies in a patient's blood that react against human leukocyte antigens (HLA). These antigens are proteins found on the surface of cells that play a crucial role in the immune system's ability to recognize which cells belong in the body and which do not.
Purpose
HLA antibody testing is primarily used for patients undergoing organ transplantation to ensure compatibility between donor and recipient. It helps prevent transplant rejection by identifying antibodies that could target the transplanted organ. The goals are to minimize the risk of organ rejection and ensure a successful transplant.
Indications
- Patients who are on the transplant list for organs such as kidneys, liver, or heart.
- Monitoring previously transplanted patients for the presence of new HLA antibodies.
- Individuals with autoimmune disorders where HLA antibodies might play a role in disease activity.
Preparation
- There are typically no specific preparations required such as fasting.
- The patient should inform the healthcare provider about any medications or supplements they are taking.
- Blood samples may be taken, so patients should be prepared for a simple blood draw.
Procedure Description
- Blood Sample Collection: A blood sample is drawn from the patient, usually from a vein in the arm.
- Separation of Serum: The blood is processed to separate the serum, where the antibodies are found.
- Solid Phase Assay: The serum is exposed to a panel of HLA antigens using methods like microspheres, beads, ELISA, or flow cytometry. These solid phase assays allow identification of specific antibodies.
- Analysis: The reaction of patient antibodies to the HLA antigens is analyzed to identify and characterize the specific HLA antibodies present.
Duration
The blood draw takes about 10-15 minutes. The entire testing process, including analysis, may take several hours to a couple of days, depending on the laboratory workflow.
Setting
The blood draw takes place in a hospital, outpatient clinic, or a specialized testing laboratory.
Personnel
- Phlebotomist or nurse for blood collection.
- Laboratory technicians and specialists in immunology or transplant medicine for conducting the assays and analysis.
- Physicians, particularly immunologists or transplant specialists, to interpret the results.
Risks and Complications
- Minor risks from blood draw such as bruising, slight bleeding, or infection at the puncture site.
- Rarely, patients might feel dizzy or faint after the blood draw.
Benefits
- Helps ensure successful organ transplantation by identifying harmful antibodies.
- Reduces the risk of transplant rejection.
- Provides essential information for managing autoimmune conditions.
Recovery
- No significant recovery time is required.
- Patients can resume normal activities immediately after the blood draw.
Alternatives
- Crossmatch tests using actual donor cells and the recipient’s serum to detect harmful antibodies.
- Virtual crossmatch using donor HLA data and the recipient's antibody profile.
- Each alternative has its own advantages and disadvantages regarding sensitivity, specificity, and applicability to urgent situations.
Patient Experience
- The patient might feel a prick and slight discomfort during the blood draw.
- Minimal pain or discomfort post-procedure.
- No significant lifestyle changes required after the procedure.
Mercury is an essential therapy monitoring and diagnostic tool for those undergoing or planning to undergo organ transplantation. It provides critical information that helps in the precision and success of transplants, improving patient outcomes and longevity of the transplanted organ.